Olumiant: Withdrawal of the application to change the marketing authorisation

baricitinib

Overview

Eli Lilly Nederland B.V. withdrew its application for the use of Olumiant in the treatment of patients hospitalised with COVID-19.

The company withdrew the application on 7 December 2022.

  • List item

    Questions and answers on the withdrawal of application to change the marketing authorisation for Olumiant (baricitinib) (PDF/130.83 KB)


    First published: 16/12/2022
    Last updated: 02/02/2023
    EMA/931846/2022

  • Key facts

    Name
    Olumiant
    Product number
    EMEA/H/C/004085
    Date of issue of market authorisation valid throughout the European Union (if applicable)
    13/02/2017
    International non-proprietary name (INN) or common name
    • baricitinib
    Active substance
    • Baricitinib
    Date of withdrawal
    07/12/2022
    Company making the application
    Eli Lilly Nederland B.V.
    Withdrawal type
    Post-authorisation

    All documents

    Related information on withdrawals

    This text will be replaced by the description of taxonomy term "Template for related information on withdrawals" from vocabulary "String replacement".

    How useful was this page?

    Add your rating